Are Gray Market Peptides Like Retatrutide Actually Safe?
The short answer from the great peptide debate of 2026: nobody fully knows, and that uncertainty is the entire argument. Gray market peptides like Retatrutide — a more aggressive GLP-1 compound that Andrew Huberman predicted could become a trillion-dollar drug — are not FDA-approved, not manufactured under regulated conditions, and have essentially no long-term human data. Yet thousands of people in Silicon Valley and beyond are already using them. That gap between anecdote and evidence is exactly where the debate lives.
On one side, Martin Shkreli argued the current peptide craze is more psychology-driven than science-driven — a passing fad among a class of people who have decided they don't need to trust experts. His position was blunt: when a proven, regulated drug like Ozempic already exists and delivers similar benefits, there is no rational reason to experiment with compounds sourced from gray markets. He wants those gray markets shut down entirely.
04:12
Martin Shkreli argues the peptide craze is psychology-driven, not science-driven
Watch at 04:12 →
On the other side, Max argued that a blanket dismissal of all peptides ignores a meaningful subset that likely has real therapeutic value. His practical point was harder to dismiss: people are already using these compounds. Given that reality, a regulated white market would reduce harm compared to the current unregulated gray market. Shutting it down doesn't make demand disappear — it just makes the supply chain more dangerous.
How Did the Debate Actually End?
It didn't — at least not with a clean verdict. The most honest summary came from a viewer in the live chat: Against: I would be worried about unknown unknowns. Pro: While there isn't much human data, the anecdotal evidence is pretty strong. Against: Anecdotes are not enough for me. Pro: They are for me. Against: Okay. Fair. That exchange captures the epistemological stalemate at the heart of this conversation. Both positions are defensible depending on your personal risk tolerance and how much weight you give to anecdotal evidence versus clinical trials.
What the debate did clarify was a rough spectrum of risk. GLP-1 drugs owned and manufactured by pharmaceutical companies and approved by the FDA — Ozempic, Wegovy, and their equivalents — sit at the safer end. Compounds like Retatrutide, available only through gray markets and not studied in large human trials, sit at the riskier end. The question of where exactly you draw your personal line is one the show left, intentionally, to viewers.
Who Is John Ternus and Will He Replace Tim Cook?
If you want to understand the future of Apple, you need to understand John Ternus. According to a detailed Bloomberg profile from Mark Gurman published March 22nd, 2026, Ternus — Apple's Senior Vice President of Hardware Engineering — has emerged as the most likely successor to Tim Cook, who turns 65 this year. Ternus oversees the development of devices that generate roughly 80 percent of Apple's revenue. He is 50 years old, has spent approximately half his life at Apple, and is younger than most of the company's other senior leaders, meaning he could potentially hold the top job for a long time.
His trajectory at the company has been deliberate and expansive. He developed computer monitors early in his career, oversaw product design for the original iPad, and eventually took over the full hardware engineering organization in 2021. More recently, he has assumed control of a secretive robotics unit — including a tabletop device with a screen that tracks speakers as they move around a room — as well as hardware and software design teams, making him a central liaison between Apple's design organization and its executive leadership.
The public signals of Cook's confidence have been unusually direct. When Apple announced the MacBook Neo — a $599 laptop — at an event in New York earlier this year, it was Ternus who did the keynote reveal, not Cook. The following day, Ternus appeared on Good Morning America to promote the device, the kind of media appearance Cook has historically handled himself. These are not subtle signals.
18:45
John Ternus steps up at Apple's MacBook Neo event in New York instead of Tim Cook
Watch at 18:45 →
Is John Ternus a Nice Guy or a Hard-Nosed Executive?
The profile paints him as both, depending on the moment. He is widely described as personable, meticulous, and collaborative — a meaningful contrast to the more demanding management culture associated with Steve Jobs. Multiple people who worked with him describe him as an outstanding leader who treats mistakes as systemic problems rather than individual failures. But that instinct has also created some internal friction, particularly in the aftermath of one of Apple's more embarrassing recent missteps.
What Went Wrong With Apple Vision Pro and AirPods?
Late in the development of the Vision Pro headset, engineers discovered a critical flaw: the then-current AirPods Pro lacked a wireless frequency required for ultra-low latency audio streaming to the headset. This feature — seamless audio from a $3,500 device to your earbuds — was central to Apple's pitch around immersive video and gaming. The only fix was to ship a revised version of the AirPods Pro, which Apple quietly did at the end of 2023.
When the Vision Pro launched in February 2024, any customer who wanted that feature had to spend another $250 on new AirPods on top of the $3,500 headset. It was an unforced error that reverberated across hardware, software, testing, and Vision Pro teams. According to the Gurman profile, the aftermath revealed something about Ternus's harder edge: he initially focused on identifying who was to blame, a response that alienated some staff. A senior AirPods executive was subsequently reassigned.
27:30
The Vision Pro AirPods compatibility debacle explained — who got blamed and why
Watch at 27:30 →
The incident matters not because it defines Ternus but because it complicates the simple narrative. He is not purely the nice guy. He has standards, and when those standards aren't met on something as fundamental to Apple's brand as device integration, he applies pressure. Whether that balance of warmth and accountability is the right formula to lead Apple through its AI transition is the open question hanging over his candidacy.
What Is OpenAI's New Nonprofit Foundation Funding?
OpenAI's newly established nonprofit foundation has announced plans to deploy $1 billion in 2026, with OpenAI co-founder Wojciech Zaremba and Jacob of Coefficient Giving stepping into leadership roles. The foundation is still searching for a permanent executive director. Sam Altman's framing of the mission is ambitious: AI will help discover new science, cure diseases, and improve quality of life in ways no single company can fully capture or fully mitigate. The risks he flagged include novel biological threats, rapid economic displacement, and complex emergent effects from highly capable models operating across society simultaneously.
The sheer scale of funding makes this potentially the best-endowed nonprofit in history, which raises interesting questions about scope. The argument for expanding into consumer technology development — rather than focusing purely on safety and societal response — is at least worth raising. OpenAI has already demonstrated that spinning out commercial products funds the nonprofit mission effectively. If the model works, why change it?
Why Did Meta Acquire Dreamer for Its AI Work Push?
Meta's Andrew Bosworth, one of the company's most trusted long-tenured executives, is taking over supervision of Meta's AI-for-work initiative — internal products designed to make the company itself operate more efficiently. The move signals a continued de-prioritization of the metaverse vision that defined an earlier chapter of Zuckerberg's strategic narrative.
Running alongside this is the acquisition of Dreamer, a startup that built a platform allowing non-technical users to create personal AI agents using plain English. Their beta — live for just one month before the acquisition — saw users building agents to manage email, plan travel, create learning tools for children, track personal finances, and achieve health goals. The co-founders and full team are joining Meta's Superintelligence Labs. The acquisition raises a natural question: will Meta AI gain native agent-building capabilities for consumers? That answer hasn't come yet, but the directional signal is hard to ignore.
Why Does the US EV Market Depend on China's CATL?
CATL — Contemporary Amperex Technology Co. Limited — is the world's largest battery company, and its founder Robin Zeng is publicly confident that American automakers will continue to need his technology regardless of the current geopolitical climate. Tesla, Ford, and GM all rely on CATL's battery technology in various forms. The company's headquarters is shaped like a giant battery cell, which is either the best or second-best piece of corporate architecture in the tech world behind Apple's spaceship campus. Zeng's position is simple: you can want energy independence, but building the alternative supply chain takes time that the market may not be willing to wait for.
